FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
1don MSN
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
Q3 2025 Management View Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to ...
John Kao: And thank you for joining us on our third quarter earnings conference call. For the third quarter of 2025, we exceeded the high end of each of our guidance metrics. Health plan membership of ...
Earnings call Alignment Healthcare delivered Q3 2025 revenue of $994M (+44% YoY) and adjusted EBITDA of $32M, exceeding the high end of guidance for the third consecutive quarter. Full-year EBITDA ...
Alignment Healthcare LLC reported its Q3 2025 earnings, surpassing expectations with an EPS of $0.02 against a forecasted loss of $0.08. The company also reported a revenue of $994 million, slightly ...
Good afternoon, and welcome to Alignment Healthcare's Fourth Quarter 2024 Earnings Conference Call and Webcast. [Operator Instructions]. Please note that this event is being recorded. Leading today's ...
Alignment Healthcare, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Alignment Healthcare, Inc. misses on earnings expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback